Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients
Scott D. Solomon,Nagesh S. Anavekar,Hicham Skali,John J.V. McMurray,Karl Swedberg,Salim Yusuf,Christopher B. Granger,Eric L. Michelson,Duolao Wang,Stuart J. Pocock,Marc A. Pfeffer +10 more
Reads0
Chats0
TLDR
LVEF is a powerful predictor of cardiovascular outcome in heart failure patients across a broad spectrum of ventricular function, and once elevated to a range above 45%, ejection fraction does not further contribute to assessment of cardiovascular risk inheart failure patients.Abstract:
Background— Left ventricular function is a principal determinant of cardiovascular risk in patients with heart failure. The growing number of patients with preserved systolic function heart failure underscores the importance of understanding the relationship between ejection fraction and risk. Methods and Results— We studied 7599 patients with a broad spectrum of symptomatic heart failure enrolled in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program. All patients were randomized to candesartan at a target dose of 32 mg once daily or matching placebo and followed up for a median of 38 months. We related left ventricular ejection fraction (LVEF), measured before randomization at the sites, to cardiovascular outcomes and causes of death. Mean LVEF in patients enrolled in CHARM was 38.8±14.9% (median LVEF 36%). Patients with lower LVEF tended to have higher baseline New York Heart Association class. The hazard ratio for all-cause mortality increased by 39% fo...read more
Citations
More filters
Journal ArticleDOI
How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology
Walter Paulus,Carsten Tschöpe,John E. Sanderson,Cesare Rusconi,Frank A. Flachskampf,Frank Rademakers,Paolo Marino,Otto A. Smiseth,Gilles W. De Keulenaer,Adelino F. Leite-Moreira,Attila Borbély,István Édes,Martin Louis Handoko,Stephane Heymans,Natalia Pezzali,Burkert Pieske,Kenneth Dickstein,Alan G. Fraser,Dirk L. Brutsaert +18 more
TL;DR: The updated strategies for the diagnosis and exclusion of HFNEF are useful not only for individual patient management but also for patient recruitment in future clinical trials exploring therapies forHFNEF.
Journal ArticleDOI
Global Public Health Burden of Heart Failure.
TL;DR: In this article, the authors focus on the global epidemiology of heart failure, providing data about prevalence, incidence, mortality and morbidity worldwide, and show geographic variations, depending on the different aetiologies and clinical characteristics observed among patients with heart failure.
Journal ArticleDOI
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial
Scott D. Solomon,Michael R. Zile,Burkert Pieske,Adriaan A. Voors,Amil M. Shah,Elisabeth Kraigher-Krainer,Victor Shi,Toni Bransford,Madoka Takeuchi,Jianjian Gong,Martin Lefkowitz,Milton Packer,John J.V. McMurray +12 more
TL;DR: In patients with heart failure with preserved ejection fraction, LCZ696 reduced NT-proBNP to a greater extent than did valsartan at 12 weeks and was well tolerated; whether these effects would translate into improved outcomes needs to be tested prospectively.
Journal ArticleDOI
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Paul A. Heidenreich,Biykem Bozkurt,David Aguilar,Larry A. Allen,Joni J. Byun,Monica Colvin,Anita Deswal,Mark H. Drazner,Shannon M. Dunlay,Linda R. Evers,James C. Fang,Savitri Fedson,Gregg C. Fonarow,Salim S. Hayek,Adrian F. Hernandez,Prateeti Khazanie,Michelle M. Kittleson,Christopher S. Lee,Mark S. Link,Carmelo A. Milano,Lorraine C. Nnacheta,Alexander T. Sandhu,Lynne W. Stevenson,Orly Vardeny,Amanda R. Vest,Clyde W. Yancy +25 more
TL;DR: The "2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure" as discussed by the authors provides patient-centric recommendations for clinicians to prevent, diagnose, and manage patients with heart failure.
Journal ArticleDOI
Irrigated Radiofrequency Catheter Ablation Guided by Electroanatomic Mapping for Recurrent Ventricular Tachycardia After Myocardial Infarction The Multicenter Thermocool Ventricular Tachycardia Ablation Trial
William G. Stevenson,David J. Wilber,Andrea Natale,Warren M. Jackman,Francis E. Marchlinski,Timothy Talbert,Mario D. Gonzalez,Seth J. Worley,Emile G. Daoud,Chun Hwang,Claudio Schuger,Thomas E. Bump,Mohammad Jazayeri,Gery Tomassoni,Harry A. Kopelman,Kyoko Soejima,Kyoko Soejima,Hiroshi Nakagawa +17 more
TL;DR: Catheter ablation is a reasonable option to reduce episodes of recurrent VT in patients with prior myocardial infarction, even when multiple and/or unmappable VTs are present, warranting surveillance and further study.
References
More filters
Journal ArticleDOI
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
Salim Yusuf,Marc A. Pfeffer,Karl Swedberg,Christopher B. Granger,Peter Held,John J.V. McMurray,Eric L. Michelson,Bertil Olofsson,Jan Östergren +8 more
TL;DR: Cedesartan has a moderate impact in preventing admissions for CHF among patients who have heart failure and LVEF higher than 40%.
Journal ArticleDOI
Effect of carvedilol on survival in severe chronic heart failure.
Milton Packer,Andrew J.S. Coats,Michael B. Fowler,Hugo A. Katus,Henry Krum,Paul Mohacsi,Jean-Lucien Rouleau,Michal Tendera,Alain Castaigne,Ellen B. Roecker,Melissa K. Schultz,David L. DeMets +11 more
TL;DR: The previously reported benefits of carvedilol with regard to morbidity and mortality in patients with mild-to-moderate heart failure were also apparent in the patients with severe heart failure who were evaluated in this trial.
Journal ArticleDOI
Effect of carvedilol on survival in severe chronic heart failure
TL;DR: In this article, the authors evaluated 2289 patients who had symptoms of heart failure at rest or on minimal exertion, who were clinically euvolemic, and who had an ejection fraction of less than 25 percent.
Journal ArticleDOI
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
Christopher B. Granger,John J.V. McMurray,Salim Yusuf,Peter Held,Eric L. Michelson,Bertil Olofsson,Jan Östergren,Marc A. Pfeffer,Karl Swedberg +8 more
TL;DR: The addition of candesartan to ACE inhibitor and other treatment leads to a further clinically important reduction in relevant cardiovascular events in patients with CHF and reduced left-ventricular ejection fraction.
Journal ArticleDOI
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
Marc A. Pfeffer,Karl Swedberg,Christopher B. Granger,Peter Held,John J.V. McMurray,Eric L. Michelson,Bertil Olofsson,Jan Östergren,Salim Yusuf +8 more
TL;DR: Codesartan was generally well tolerated and significantly reduced cardiovascular deaths and hospital admissions for heart failure and there was no significant heterogeneity for candesartan results across the component trials.
Related Papers (5)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.
Piotr Ponikowski,Adriaan A. Voors,Stefan D. Anker,Héctor Bueno,John G.F. Cleland,Andrew J.S. Coats,Volkmar Falk,José Ramón González-Juanatey,Veli-Pekka Harjola,Ewa A. Jankowska,Mariell Jessup,Cecilia Linde,Petros Nihoyannopoulos,John Parissis,Burkert Pieske,Jillian P. Riley,Giuseppe M.C. Rosano,Luis M. Ruilope,Frank Ruschitzka,Frans H. Rutten,Peter van der Meer,Gerasimos Filippatos,John J.V. McMurray,Victor Aboyans,Stephan Achenbach,Stefan Agewall,Nawwar Al-Attar,John Atherton,Johann Bauersachs,A. John Camm,Scipione Carerj,Claudio Ceconi,Antonio Coca,Perry M. Elliott,Çetin Erol,Justin A. Ezekowitz,Covadonga Fernández-Golfín,Donna Fitzsimons,Marco Guazzi,Maxime Guenoun,Gerd Hasenfuss,Gerhard Hindricks,Arno W. Hoes,Bernard Iung,Tiny Jaarsma,Paulus Kirchhof,Juhani Knuuti,Philippe Kolh,Stavros Konstantinides,Mitja Lainscak,Patrizio Lancellotti,Gregory Y.H. Lip,Francesco Maisano,Christian Mueller,Mark C. Petrie,Massimo F Piepoli,Silvia G. Priori,Adam Torbicki,Hiroyuki Tsutsui,Dirk J. van Veldhuisen,Stephan Windecker,Clyde W. Yancy,José Luis Zamorano +62 more
2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Clyde W. Yancy,Mariell Jessup,Biykem Bozkurt,Javed Butler,Donald E. Casey,Mark H. Drazner,Gregg C. Fonarow,Stephen A. Geraci,Tamara B. Horwich,James L. Januzzi,Maryl R. Johnson,Edward K. Kasper,Wayne C. Levy,Frederick A. Masoudi,Patrick E. McBride,John J.V. McMurray,Judith E. Mitchell,Pamela N. Peterson,Barbara Riegel,Flora Sam,Lynne W. Stevenson,W.H. Wilson Tang,Emily J. Tsai,Bruce L. Wilkoff +23 more
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski,Adriaan A. Voors,Stefan D. Anker,Héctor Bueno,John G.F. Cleland,Andrew J.S. Coats,Volkmar Falk,José Ramón González-Juanatey,Veli-Pekka Harjola,Ewa A. Jankowska,Mariell Jessup,Cecilia Linde,Petros Nihoyannopoulos,John Parissis,Burkert Pieske,Jillian P. Riley,Giuseppe M.C. Rosano,Luis M. Ruilope,Frank Ruschitzka,Frans H. Rutten,Peter van der Meer +20 more